Exenatide once weekly in type 2 diabetes

The Lancet

Volumn 372, Issue 9645, 2008, Pages 1197-1198

  Scheen, Andre J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIPHASIC INSULIN; EXENDIN 4; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MAXIMUM TOLERATED DOSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 53149113746     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61207-6     Document Type: Note

References (15)

1. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
2. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49 (2006) 1711-1721
3. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Update regarding the thiazolidinediones. Diabetologia 51 (2008) 8-11
4. Holman R.R., Thorne K.I., Farmer A.J., et al., for the 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357 (2007) 1716-1730
5. Peyrot M., Rubin R.R., Lauritzen T., et al., on behalf of the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
6. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
7. Cvetkovic R.S., and Plosker G.L. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 67 (2007) 935-954
8. Van Gaal L.F., Gutkin S.W., and Nauck M.A. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists or insulin for patients with inadequate glycemic control?. Eur J Endocrinol 158 (2008) 773-784
9. Odegard P.S., and Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 33 (2007) 1014-1029
10. Drucker D.J., Buse J.B., Taylor K., et al., for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 10.1016/S0140-6736(08)61206-4 published online Sept 8.
11. Nathan D.M. Finding new treatments for diabetes: how many, how fast and how good?. N Engl J Med 365 (2007) 437-440
12. Visbøll T. Liraglutide: a once-daily GLP-1 analogue for the treatment for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 16 (2007) 231-237
13. Edwards K.L., Alvarez C., Irons B.K., and Fields J. Third-line selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. Pharmacotherapy 28 (2008) 506-521
14. Guerci B., and Martin C.S. Exenatide. Its position in the treatment of type 2 diabetes. Ann Endocrinol 69 (2008) 201-209
15. Home P., Mant J., Diaz J., Turner C., and on behalf of the Guideline Development Group. Management of type 2 diabetes: summary of updated NICE guidance. BMJ 336 (2008) 1306-1308